TSPYL1

TSPYL1 is a nuclear nucleosome assembly protein (NAP)-domain protein that acts as a transcriptional repressor governing cell-cycle progression, TGFβ/SMAD signaling, and drug-metabolizing gene expression (PMID:33075815, PMID:38588050). It represses TGFBR1 and TSPYL2 by partnering with the transcription factor FOXA1 and the histone methyltransferase EZH2; loss of TSPYL1 de-represses TGFBR1, amplifies TGFβ signaling, and stabilizes TSPYL2, which joins the SMAD2/3/4 complex to drive transcriptional responses including EMT, an effect reversed by TSPYL2 depletion (PMID:38588050). TSPYL1 also represses a panel of cytochrome P450 genes including CYP17A1, CYP3A4, and CYP2C19, as well as the serotonin transporter SLC6A4; the common Pro62Ser variant (rs3828743) impairs CYP repression, lowering abiraterone exposure and increasing prostate cancer cell proliferation (PMID:29027195, PMID:31628858). Frameshift truncations that remove the NAP domain abolish nuclear localization and mislocalize the protein to the Golgi, and TSPYL1-deficient cells show prolonged S and G2 phases with reduced proliferation, while Tspyl1 depletion in zebrafish causes early lethality, neurogenesis defects, and cardiac dilation consistent with the lethal SIDDT syndrome (PMID:15273283, PMID:33075815).

1. 2004 Medium

   Established that a disease-associated frameshift mutation truncates TSPYL1 to remove its NAP domain and an associated nuclear localization signal, defining the molecular basis of SIDDT as loss of nuclear function.

   Evidence Patient DNA sequencing and GFP-fusion subcellular localization of the truncated protein

   PMID:15273283

   Open questions at the time

   • Did not define the nuclear function lost
   • No identification of binding partners or transcriptional targets
2. 2005 Medium

   Identified ZFP106 as a TSPYL1 interaction partner recruited into nucleoplasmic bodies through a domain absent in the disease mutant, linking a specific protein interaction to the SIDDT mechanism.

   Evidence Yeast two-hybrid screen, co-localization imaging, and deletion analysis

   PMID:15833274

   Open questions at the time

   • Functional consequence of ZFP106 recruitment unresolved
   • Interaction not validated by reciprocal endogenous Co-IP
3. 2017 Medium

   Defined TSPYL1 as a transcriptional repressor of CYP17A1 and CYP3A4 and showed a common coding SNP abolishes this repression, connecting TSPYL1 to drug metabolism and prostate cancer pharmacology.

   Evidence Knockdown/overexpression, reporter assays, SNP functional analysis, and clinical pharmacokinetics

   PMID:29027195

   Open questions at the time

   • Mechanism of promoter targeting not defined
   • Direct binding to CYP loci not established
4. 2019 Medium

   Extended TSPYL1 repressor activity to CYP2C19 and to the serotonin transporter SLC6A4, showing the rs3828743 variant weakens repression and altering serotonin transport.

   Evidence Knockdown/overexpression with CYP/SLC6A4 expression and serotonin transport assays

   PMID:31628858

   Open questions at the time

   • Co-regulators mediating repression unidentified
   • In vivo relevance of serotonin transport effect untested
5. 2020 High

   Demonstrated that NAP-domain loss mislocalizes TSPYL1 to the Golgi and that TSPYL1 deficiency impairs cell-cycle progression and produces developmental defects in vivo, tying the molecular lesion to cellular and organismal phenotypes.

   Evidence Exome sequencing, patient fibroblast localization, flow-cytometry cell-cycle analysis, nuclear proteomics, and zebrafish morpholino knockdown

   PMID:33075815

   Open questions at the time

   • Transcriptional targets driving cell-cycle delay not pinpointed
   • Mechanistic link between Golgi mislocalization and loss of function unresolved
6. 2024 High

   Placed TSPYL1 in a defined repressor complex with FOXA1 and EZH2 controlling TGFBR1 and TSPYL2, establishing a TSPYL1–TSPYL2 axis that restrains TGFβ/SMAD-driven EMT.

   Evidence siRNA knockdown, Co-IP, ChIP, protein stability assays, and TSPYL2-depletion rescue of EMT in A549 cells

   PMID:38588050

   Open questions at the time

   • Whether the same FOXA1/EZH2 complex governs CYP gene repression untested
   • Genome-wide TSPYL1 occupancy not mapped

• How TSPYL1's NAP domain mechanistically achieves transcriptional repression and target selectivity, and whether its chromatin/nucleosome activity unifies its CYP, TGFβ, and cell-cycle roles, remains unresolved.
• No direct nucleosome assembly/biochemical activity demonstrated
• No structural model of TSPYL1 or its complexes
• Mechanism linking NAP-domain loss to Golgi retention unknown